SHC007
MISSION® pLKO.1-puro Luciferase shRNA Control Plasmid DNA
shRNA sequence targeting luciferase
Synonym(s):
MISSION® Control Vectors
Sign In to View Organizational & Contract Pricing.
Select a Size
1 PKG
$441.00
About This Item
Concentration:
500 ng/μL in TE buffer; DNA (10μg of plasmid DNA)
Skip To
Looking for similar products? Visit Product Comparison Guide
Related Categories
1 of 4
This Item | SHC005 | SHC004 | SHC003 |
|---|---|---|---|
| product line MISSION® | product line MISSION® | product line MISSION® | product line MISSION® |
| concentration 500 ng/μL in TE buffer; DNA (10μg of plasmid DNA) | concentration 500 ng/μL in TE buffer; DNA (10μg of plasmid DNA) | concentration 500 ng/μL in TE buffer; DNA (10μg of plasmid DNA) | concentration 500 ng/μL in TE buffer; DNA (10μg of plasmid DNA) |
| shipped in dry ice | shipped in dry ice | shipped in dry ice | shipped in dry ice |
| storage temp. −20°C | storage temp. −20°C | storage temp. −20°C | storage temp. −20°C |
| Quality Level 200 | Quality Level 200 | Quality Level 200 | Quality Level 200 |
General description
The MISSION® Luciferase shRNA Control Vector is a 7,091 base pair lentivirus plasmid vector that contains an shRNA sequence targeting luciferase from Photinus pyralis (GenBank Accession No. M15077). The Luciferase shRNA Control Vector is useful as a positive knockdown control in experiments using cell lines expressing firefly luciferase. It can also be used as a negative control vector.[1][2][3]
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids, MISSION® Lentiviral Packaging Mix (Prod. No. SHP001). The Luciferase shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Ampicillin and puromycin antibiotic resistance genes provide selection in bacterial or mammalian cells respectively. In addition, self-inactivating replication incompetent viral particles can be produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids, MISSION® Lentiviral Packaging Mix (Prod. No. SHP001). The Luciferase shRNA Control Vector is provided as 10 μg of plasmid DNA in Tris-EDTA (TE) buffer at a concentration of 500 ng/μl.
Application
To see more application data, protocols, vector maps visit sigma.com/shrna.
Legal Information
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense.
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
related product
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Vajiheh Neshati et al.
Applied biochemistry and biotechnology, 186(1), 245-255 (2018-03-27)
Since the adult mammalian heart has limited regenerative capacity, cardiac trauma, disease, and aging cause permanent loss of contractile tissue. This has fueled the development of stem cell-based strategies to provide the damaged heart with new cardiomyocytes. Bone marrow-derived mesenchymal
Deepak Bararia et al.
Nature communications, 7, 10968-10968 (2016-03-24)
CCAAT/enhancer-binding protein alpha (C/EBPα) is an essential transcription factor for myeloid lineage commitment. Here we demonstrate that acetylation of C/EBPα at lysine residues K298 and K302, mediated at least in part by general control non-derepressible 5 (GCN5), impairs C/EBPα DNA-binding
Islands of spatially discordant APD alternans underlie arrhythmogenesis by promoting electrotonic dyssynchrony in models of fibrotic rat ventricular myocardium.
Majumder R
Scientific Reports, 6 (2016)
The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.
Giotopoulos G
Oncogene, 35(3), 279-289 (2016)
Victoria J Gennaro et al.
BMC cancer, 19(1), 258-258 (2019-03-25)
The oncoprotein MYC has the dual capacity to drive cell cycle progression or induce apoptosis, depending on the cellular context. BAG1 was previously identified as a transcriptional target of MYC that functions as a critical determinant of this cell fate
Related Content
Instructions
Instructions
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service